ABSTRACT
Ganglioside and carbohydrate antigens (Ag) exposed on the cell surface are targets for passive immunotherapy using murine [1,2], human [3,4], and genetically engineered monoclonal anti-carbohydrate antibodies (Ab) [5]. They are also the basis for active specific immunotherapy using vaccines made of either purified carbohydrate Ag [6,7] or whole cells that overex press carbohydrate Ag [8,9]. One of the prerequisites for targeting tumor cell-surface ganglioside and carbohydrate Ag for specific immunotherapies (passive and active) is a high density of expression on the cell surface [1,10].
